According to the newspaper "Daily mail"Britons, drug trials have shown that the chances of living longer increase by a third Men that had not previously been taken care of.
The drug works by blocking it Androgen receptors In cancer cells, which in turn blocks the effect of testosterone, which allows cancer cells to survive and multiply.
The health service said it would start supplying the drug to patients Prostate cancer Qualified within weeks.
Prostate cancer is the most common type cancer More common in men, it is diagnosed in around 47,000 people each year in England.
Amanda Pritchard, chief executive of the NHS, said: "It is remarkable that patients in England are the first in Europe to receive this treatment for an advanced and severe form of prostate cancer".
Chiara De Biasi, Director of Support and Impact at Prostate Cancer UK, said:" Being told you have advanced prostate cancer can be devastating and we urgently need new treatments to help these men live longer.".
In turn, the National Director of Cancer at the Authority, Professor Peter Johnson, said: "We know it cancer Prostate is the most common form of cancer among men, and it’s vital we continue to diagnose patients as early as possible and expand our arsenal of cutting-edge treatments to increase people’s chances of survival.".
added: "This innovative treatment builds on our ambition to improve care cancer patients and survival rates and will help thousands of men diagnosed with prostate cancer live better lives by reducing their chances of dying by a third.".
“>
It will become the National Health Service United Kingdomthe first healthcare provider to introduce darulutamide to patients whose prostate cancer has spread to other parts of the body.
According to the British newspaper “Daily Mail”, drug trials have shown that the chances of living longer increase by a third Men that had not previously been taken care of.
The drug works by blocking it Androgen receptors In cancer cells, which in turn blocks the effect of testosterone, which allows cancer cells to survive and multiply.
The health service said it would start supplying the drug to patients Prostate cancer Qualified within weeks.
Prostate cancer is the most common type cancer More common in men, it is diagnosed in around 47,000 people each year in England.
Amanda Pritchard, chief executive of the NHS, said: “It’s great that patients in England are the first in Europe to receive this treatment for advanced and aggressive prostate cancer.”
Chiara De Biasi, director of support and impact at charity Prostate Cancer UK, said: ‘Learning you have advanced prostate cancer can be devastating and we urgently need new treatments to help these men live longer. long”.
In turn, the authority’s national cancer director, Professor Peter Johnson, said: ‘We know that… cancer Prostate is the most common form of cancer among men, and it’s vital we continue to diagnose patients as early as possible and expand our arsenal of cutting-edge treatments to increase people’s chances of survival.”
He added: “This innovative treatment builds on our ambition to improve care cancer patients and survival rates and will help thousands of men diagnosed with prostate cancer live better lives by reducing their chances of dying by a third.”
